Major Research Areas

Selected Publications

Houghton AN. Building a better monoclonal antibody. Immunol Today. 1988; 9:265-267

Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO. Vaccination of high-risk breast cancer patients with mucin-1 (MUCI) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res. 2000;6:1693-1701.

Janetzki S, Song P, Gupta V, Lewis JJ, Houghton AN. Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay. J Immunol Methods. 2000;234:1-12.

Wang S, Bartido S, Yang G, Qin J, Moroi Y, Panageas KS, Lewis JJ, Houghton AN. A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell response. J Immunol. 1999;163:5820-5826.

Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clin Cancer Res. 1999;5:1319-1323.

Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res. 1999;5:77-81.

Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, Piskun G, Lewis JJ, Houghton AN, Nikolic-Zugic J. Heteroclitic immunization induces tumor immunity. J Exp Med. 1998;188:1553-1561.

Hirschowitz E, Leonard S, Song W, Ferris B, Leopold PL, Lewis J, Bowne B, Wang S, Houghton AN, Crystal RG. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther. 1998;5:975-983.

Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest. 1998;102:1258-1264.

Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch J. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA. 1998;95:652-656.

Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA. 1996;93:14809-14814.

Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA. 1985;82:1242-1246.

Houghton AN, Vijayasaradhi S, Bouchard B, Naftzger C, Hara I, Chapman PB. Recognition of autoantigens by patients with melanoma. Ann N Y Acad Sci. 1993;690:59-68.

Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA. 1996;93:14809-14814.

Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Ottegen HF, Old LJ, Houghton AN. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of an inflammatory response at tumor sites. J Clin Onc. 1988;6:1636-1648.

Hawkins WG, Gold JS, Dyall R, Wolchok J, Hoos A, Bowne WB, Srinivasan R, Houghton AN, Lewis JJ. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery. 2000;128:273-280.

McCaffery M, Yao T-J, Williams L, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res. 1996;2:679-686.

Gansbacher B, Zier K, Cronin K, Hantzopoulos PA, Bouchard A, Houghton A, Gilboa E, Golde D. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood. 1993;80:2817-2825.

Jakubowski AN, Bajorin DF, Templeton MA, Chapman PB, Cody BV, Thaler H, Tao Y, Filippa DA, Williams L, Sherman ML, Garnick MB, Houghton AN. Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma. Clin Cancer Res. 1996;2:295-302.

Minasian LM, Szatrowski TP, Rosenblum M, Steffens T, Morrison ME, Chapman PB, Williams L, Nathan CF, Houghton AN. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood. 1994;83:56-64.

McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside): enhanced immunogenicity when combined with adjuvant. Clin Cancer Res. 1996;679-686.

Minasian LM, Yao TJ, Steffens TA, Scheinberg DA, Williams L, Riedel E, Houghton AN, Chapman PB. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer. 1995; 75:2251-2257.

Brooks D, Taylor C, Dos Santos B, Linden H, Houghton A, Hecht TT, Kornfeld S, Taetle R. Phase Ia trial of murine immunoglobin A antitransferrin receptor antibody 42/6. Clin Cancer Res. 1995;1:1259-1265.

Houghton AN. On course for a cancer vaccine. Lancet. 1995;345:1384-1385.

Yuasa H, Scheinberg DA, Houghton AN. Gangliosides of T lymphocytes: evidence for a role in T-cell activation. Tissue Antigens. 1990;35:47-56.

Janetzki S, Song P, Gupta V, Lewis JJ, Houghton AN. Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay. J Immunol Methods. 2000;234:1-12.

Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma. Cur Opin Immunol. 2001;13:134-40.

Lewis JJ, Janetzki S, Schaed S, Panageas KS, Wang S, Williams L, Meyers M, Butterworth L, Livingston PO, Chapman PB, Houghton AN. Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer. 2000;87:391-8.

Vadhan-Raj S, Cordon-Cardo C, Carswell E, Minzter D, Dantis L, Duteau C, Templeton MA, Ottegen HF, Old LJ, Houghton AN. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of an inflammatory response at tumor sites. J Clin Onc. 1988;6:1636-1648.

Return to Development of Cancer Vaccines and Monoclonal Antibodies for Cancer Therapy Main Page

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2008 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org